ERCC1, hRad51, and BRCA1 protein expression in relation to tumour response and survival of stage III/IV NSCLC patients treated with chemotherapy

• Published in: Lung cancer (Amsterdam, Netherlands) Netherlands), 2005-11, Vol.50 (2), p.211-219
• Main Authors: Wachters, F.M., Wong, L.S.M., Timens, W., Kampinga, H.H., Groen, H.J.M.
• Format: Article
• Language: English
• Subjects: Adult; Aged; Biological and medical sciences; Biopsy; BRCA1; BRCA1 Protein - biosynthesis; Carcinoma, Non-Small-Cell Lung - drug therapy; Carcinoma, Non-Small-Cell Lung - genetics; Chemotherapy; DNA Damage; DNA Repair; DNA-Binding Proteins - biosynthesis; Endonucleases - biosynthesis; ERCC1; Female; Gemcitabine; Gene Expression Profiling; Homologous recombination; hRad51; Humans; Immunohistochemistry; Lung Neoplasms - drug therapy; Lung Neoplasms - genetics; Male; Medical sciences; Middle Aged; Non-small-cell lung cancer; Nucleotide excision repair; Pneumology; Predictive Value of Tests; Prognosis; Rad51 Recombinase - biosynthesis; Survival Analysis; Tumors of the respiratory system and mediastinum
• ISSN: 0169-5002; 1872-8332
• DOI: 10.1016/j.lungcan.2005.06.013

Aim of this explorative study was to determine the prognostic value of protein expression of the DNA damage repair enzymes ERCC1, hRad51, and BRCA1 for tumour response and survival of non-small-cell lung cancer patients treated with chemotherapy. Patients with either a short or long overall survival were selected from a randomized phase III trial comparing cisplatin–gemcitabine and epirubicin–gemcitabine. Tumour biopsies were assessed for differences in immunohistochemical staining using antibodies against ERCC1, hRad51, and BRCA1. A total of 33 patients were included. A positive nuclear staining for ERCC1, hRad51, and BRCA1 was observed in 44, 12, and 90% of biopsies, respectively. In large cell carcinoma nuclear hRad51 staining was absent. In five biopsies stained for hRad51 an unexpected membrane-like staining was observed; these biopsies showed no nuclear staining. DNA damage repair protein expressions were not significantly different in responders versus non-responders, or in patients with a short or long overall survival. In conclusion, immunohistochemical staining of ERCC1, hRad51, and BRCA1, in tumour biopsies from non-small-cell lung cancer patients was not predictive for tumour response and survival after chemotherapy.